High-Intensity Perfusion CHO Medium Supports Efficient And Consistently High mAb Production And Product Quality In Continuous Perfusion With CHO-K1 Cells

Continuous perfusion (CP) processes have redefined efficiency in biotherapeutic manufacturing, offering unparalleled advantages in product quality and scalability. Historically developed to overcome challenges with cytotoxic and low-production molecules, CP enables a stable cell culture environment, sustaining high viabilities and densities exceeding 100 million cells/mL. However, the broader adoption of CP was hindered by gaps in technology and the dominance of fed-batch processes.

Today, as scalability limits of fed-batch systems emerge, innovative solutions like the Gibco™ High-Intensity Perfusion (HIP) CHO Medium are addressing these challenges head-on. This single-part, chemically defined, animal origin-free formulation is optimized for CHO cell cultures, delivering consistent high productivity and quality. Supported by advanced bioprocessing technologies and validated through rigorous studies with CHO-K1 cells, HIP CHO Medium exemplifies the potential of CP to not only meet but exceed the demands of modern biopharmaceutical production.

This paper explores its efficacy, scalability, and integration into continuous and intensified production platforms.